Elegen Bio Logo
Order Now
Linkedin-in X-twitter

Early Access Program - GEN II

Automated, miniaturized microfluidic DNA synthesis technology

Elegen’s Gen II, fully automated, and fully cell-free DNA manufacturing platform will be coming online early next year.

Powered by Elegen’s patented microfluidic DNA synthesis technology, The Gen II platform enables Elegen to offer high-quality DNA products at speeds and costs superior to market-leading gene synthesis suppliers who still rely on cells.

With Gen II entering production, Elegen will deliver the world’s first fully cell-free, capital-efficient DNA manufacturing platform — producing high-quality linear DNA from oligos to genes and poly(A)-tailed IVT templates, all in a compact, deployable system.

Elegen is offering early access to select customers. Register now to secure your spot.

  • Rapid, high complexity, NGS-verified DNA production to fuel the AI era of Genetic Medicine.

  • Reliable, high-quality, high-diversity linear DNA free of the risks and drawbacks of cell-based gene synthesis.

  • The only fully-automated, miniaturized, high-throughput clinical-ready DNA production platform capable of efficiently scaling personalized therapeutics.

  • More throughput per square foot: ~11x more genes per sq ft per month.

  • Minimal operating overhead.

  • Pricing lower than market leaders.

  • Turnaround time faster than market leaders.

  • Eliminates 90% of the labor and capital associated with cell-based DNA synthesis.

Register Now